Abstract
In preparation of a clinical phase I/II study in renal cell carcinoma (RCC) patients, we developed a clinically applicable protocol that meets good clinical practice (GCP) criteria regarding the gene transduction and expansion of primary human T lymphocytes. We previously designed a transgene that encodes a single chain (sc) FvG250 antibody chimeric receptor (ch-Rec), specific for a RCC tumor-associated antigen (TAA), and that genetically programs human T lymphocytes with RCC immune specificity. Here we describe the conditions for activation, gene transduction, and proliferation for primary human T lymphocytes to yield: (a) optimal functional expression of the transgene; (b) ch-Rec–mediated cytokine production, and (c) cytolysis of G250-TAAPOS RCC by the T-lymphocyte transductants. Moreover, these parameters were tested at clinical scale, i.e., yielding up to 5–10×109 T-cell transductants, defined as the treatment dose according to our clinical protocol. The following parameters were, for the first time, tested in an interactive way: (1) media compositions for production of virus by the stable PG13 packaging cell; (2) T-lymphocyte activation conditions and reagents (anti-CD3 mAb; anti-CD3+anti-CD28 mAbs; and PHA); (3) kinetics of T-lymphocyte activation prior to gene transduction; (4) (i) T-lymphocyte density, and (ii) volume of virus-containing supernatant per surface unit during gene transduction; and (5) medium composition for T-lymphocyte maintenance (i) in-between gene transduction cycles, and (ii) during in vitro T-lymphocyte expansion. Critical to gene transduction of human T lymphocytes at clinical scale appeared to be the use of the fibronectin fragment CH-296 (Retronectin™) as well as Lifecell® X-fold™ cell culture bags. In order to comply with GCP requirements, we used: (a) bovine serum-free human T-lymphocyte transduction system, i.e., media supplemented with autologous patients' plasma, and (b) a closed cell culture system for all lymphocyte processing. This clinical protocol routinely yields 30–65% scFvG250 ch-RecPOS T lymphocytes in both healthy donors and RCC patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rosenberg SA, Yannelli J, Yang J et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 J Natl Cancer Inst 1994 86: 1159–1166
Falkenburg JH, Wafelman AR, Joosten P et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes Blood 1999 94: 1201–1208
Lanzavecchia A, Scheidegger D . The use of hybrid hybridomas to target human cytotoxic T lymphocytes Eur J Immunol 1987 17: 105–111
Van Dijk J, Warnaar SO, Van Eendenburg JDH et al. Induction of tumour cell lysis by bi-specific monoclonal antibodies recognizing renal cell carcinoma and CD3 antigen Int J Cancer 1989 43: 344–349
Mezzanzanica D, Garrido MA, Neblock DS et al. Human T lymphocytes targeted against an established human ovarian carcinoma with a bi-specific F(ab′)2 antibody prolong host survival in a murine xenograft model Cancer Res 1991 5: 5716–5721
Bolhuis RLH, Lamers CHJ, Goey SH et al. Adoptive immunotherapy of ovarian carcinoma with Bs-Mab–targeted lymphocytes: a multi-center study Int J Cancer 1992 7: 78–81
Renner C, Jung W, Sahin U et al. Cure of xenografted human tumours by bi-specific antibodies and human T cells Science 1994 264: 833–835
Canevari S, Stoter G, Arienti F et al. Regression of advanced ovarian carcinoma by intra-peritoneal treatment with autologous T lymphocytes retargeted by a bi-specific monoclonal antibody J Natl Cancer Inst 1995 19: 1463–1469
Jain RK . Delivery of novel therapeutic agents in tumours: physiological barriers and strategies J Natl Cancer Inst 1989 81: 570–576
Blank-Voorthuis CJAC, Braakman E, Ronteltap CPM et al. Clustered CD3/TCR complexes do not transduce activation signals following bi-specific monoclonal antibody triggered lysis by CTL via CD3 J Immunol 1993 151: 2904–2914
Lamers CHJ, Gratama JW, Warnaar SO et al. Inhibition of bi-specific monoclonal antibody (bs-Ab)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated lymphocytes Int J Cancer 1995 60: 450–457
Eshhar Z, Waks T, Gross G, Schindler DG . Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the g or z subunits of the immunoglobulin and T-cell receptors Proc Natl Acad Sci USA 1993 90: 720–724
Hwu P, Shafer GE, Treisman J et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain J Exp Med 1993 17: 361–366
Roberts MR, Qin L, Zhang D et al. Targeting of human immune deficiency virus–infected cells by CD8+ T lymphocytes armed with universal T-cell receptors Blood 1994 84: 2878–2889
Harris DT . Hormonal therapy and chemotherapy of renal-cell carcinoma Semin Oncol 1983 10: 422–430
Kruit WHJ, Goey SH, Lamers CHJ et al. High-dose regimen of interleukin-2 (IL2) and interferon-alpha (IFNα) in combination with lymphokine-activated killer cells (LAK) in patients with metastatic renal cell cancer J Immunother 1997 20: 312–322
Oosterwijk E, Ruiter DJ, Hoedemaeker PHJ et al. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney Int J Cancer 1986 38: 489–494
Oosterwijk E, Debruyne FMJ, Schalken JA . The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma Semin Oncol 1995 2: 34–41
Steffens MG, Boerman OC, Oosterwijk-Wakka JC et al. Targeting of renal cell carcinoma with Iodine-131–labeled chimeric monoclonal antibody G250 J Clin Oncol 1997 15: 1529–1537
Steffens MG, Boerman OC, Oyen WJG et al. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy Cancer Res 1999 59: 1615–1619
Weijtens MEM, Willemsen RA, Valerio D, Stam K, Bolhuis RLH . Single chain Ig/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity J Immunol 1996 157: 836–843
Weijtens ME, Willemsen RA, Hart E, Bolhuis RLH . A retroviral vector system “Stitch” in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient transduction and expression in human T lymphocytes Gene Ther 1998 5: 1195–1203
Weijtens MEM, Willemsen RA, Van Krimpen BA, Bolhuis RLH . Chimeric scFv/gamma receptor–mediated T cell lysis of tumor cells is co-regulated by adhesion and accessory molecules Int J Cancer 1998 77: 181–187
Weijtens MEM, Hart EH, Bolhuis RLH . Functional balance between T cell chimeric receptor density and tumor-associated antigen density: CTL mediated cytolysis and lymphokine production Gene Ther 2000 7: 35–42
Miller AD, Garcia JV, Suhr Von N, Lynch CM, Wilson C, Eiden MV . Construction and properties of retrovirus packaging cells based on Gibbon Ape Leukemia Virus J Virol 1991 2220–2224
Lamers CHJ, Van De Griend RJ, Braakman E et al. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bi-specific antibody-directed cellular immunotherapy Int J Cancer 1992 51: 973–979
Lamers CHJ, Gratama JW, Van Putten WLJ, Stoter G, Bolhuis RLH . Exogenous IL-2 recruits in vitro LAK activity by in vivo activated lymphocytes Cancer Res 1991 51: 2324–2328
Pollok KE, Hanenberg H, Noblitt TW et al. High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments J Virol 1998 72: 4882–4892
Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, Williams DA . Co-localization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells Nature Med 1996 2: 876–882
Gratama JW, Zea AH, Bolhuis RLH, Ochoa AC . Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy Cancer Immunol Immunother 1999 48: 263–269
Finke JH, Zea AH, Stanley J et al. Loss of T-cell receptor ξ chain and p56lck in T-cells infiltrating human renal cell carcinoma Cancer Res 1993 53: 5613–5618
Hwu P, Yang JC, Cowherd R et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes Cancer Res 1995 55: 3369–3373
Altenschmidt U, Klundt E, Groner B . Adoptive transfer of in vitro–targeted, activated T lymphocytes results in total tumor regression J Immunol 1997 159: 5509–5515
Wang G, Chopra RK, Royal RE, Yang JC, Rosenberg SA, Hwu P . A T cell–independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen Nat Med 1998 4: 168–172
McGuinness PR, Ge Y, Patel SD et al. Anti-tumor activity of human T cells expressing the CC49-ζ chimeric immune receptor Hum Gene Ther 1999 10: 165–173
Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI . Efficient transfer of a tumor-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity J Immunol 1999 163: 507–513
Willemsen RA, Weijtens MEM, Ronteltap C et al. Genetic programming of primary human T lymphocytes with cancer specific chimeric single chain and two chain TCR Gene Ther 2000 7: 1369–1377
Cooper LJN, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD . Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes J Virol 2000 74: 8207–8212
Stanislawski T, Voss RV, Lotz C et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer Nat Immunol 2001 2: 962–970
Bunnell BA, Muul LM, Donahue RE, Blaese RM, Morgan RA . High-efficiency retroviral-mediated gene transfer into human and non-human primate peripheral blood lymphocytes Proc Natl Acad Sci USA 1995 92: 7739–7743
Shimizu Y, Van Seventer GA, Horgan KJ, Shaw S . Regulation of expression and binding of three VLA (β1) integrin receptors on T cells Nature 1990 345: 250–253
Pollok KE, Van Der Loo JCM, Cooper RJ, Kennedy L, Williams DA . Co-stimulation of transduced T lymphocytes via T cell receptor–CD3 complex and CD28 leads to increased transcription of integrated retrovirus Hum Gene Ther 1999 10: 2221–2236
Garlie NK, Siebenlist RE, Lefever AV . T cells activated in vitro as immunotherapy for renal cell carcinoma: characterization of 2 effector T-cell populations J Urol 2001 166: 299–303
Acknowledgements
The authors thank Brigitte van Krimpen and Pascal van Elzakker for their technical assistance; Nexell International for kindly providing Lifecell® X-fold™ culture bags; and Takara Shuzo (Otsu, Shiga, Japan) for kindly providing fibronectin fragment CH-296 (Retronectin™). The work was supported by the Dutch Technology Foundation STW (project RGN.3498), the Dutch Cancer Society (Nederlandse Kankerbestrijding project DDHK99-1865), the Cancer Research Institute (New York, NY, USA), and the EU Grant QLK3-1999-01-262.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lamers, C., Willemsen, R., Luider, B. et al. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther 9, 613–623 (2002). https://doi.org/10.1038/sj.cgt.7700477
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700477
Keywords
This article is cited by
-
Effects of polybrene and retronectin as transduction enhancers on the development and phenotypic characteristics of VHH-based CD19-redirected CAR T cells: a comparative investigation
Clinical and Experimental Medicine (2022)
-
Optimized retroviral transduction of mouse T cells for in vivo assessment of gene function
Nature Protocols (2017)
-
T-cell receptor transfer into human T cells with ecotropic retroviral vectors
Gene Therapy (2014)
-
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial
Cancer Immunology, Immunotherapy (2014)
-
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
Molecular Therapy (2013)